Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Asian Phytoceuticals PCLBKK:APCO-R 62 Capex-to-Operating-Income is 0.07 as of Jun. 2026, which is 250% above its 10-year median of 0.02. GuruFocus rates BKK:APCO-R with a GF Score™ of 62/100 and a GF Value™ of ฿7.87. The stock has 4 warning signs investors should review. Among 1,159 Consumer Packaged Goods companies, Asian Phytoceuticals PCL ranks better than 96.98% on this metric.
Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.
Asian Phytoceuticals PCL (BKK:APCO-R) Capex-to-Operating-Income Explanation
Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.
Asian Phytoceuticals PCL Capex-to-Operating-Income Related Terms
Asian Phytoceuticals PCL Capex-to-Operating-Income Historical Data
* Premium members only.
The historical data trend for Asian Phytoceuticals PCL's Capex-to-Operating-Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asian Phytoceuticals PCL Capex-to-Operating-Income Chart
BKK:APCO-R vs PG, CL, EL: Capex-to-Operating-Income Comparison
For the Household & Personal Products subindustry, Asian Phytoceuticals PCL's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asian Phytoceuticals PCL Capex-to-Operating-Income vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Asian Phytoceuticals PCL's Capex-to-Operating-Income distribution charts can be found below:
* The bar in red indicates where Asian Phytoceuticals PCL's Capex-to-Operating-Income falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Capex-to-Operating-Income of 0.07 mean?
Asian Phytoceuticals PCL (BKK:APCO-R) has a Capex-to-Operating-Income of 0.07 as of Jun. 2026. Capex to Operating Income ratio measures a company's investments in physical assets to its operating income. View historical data on Asian Phytoceuticals PCL and its competitors. This is 250% above median its historical median of 0.02. According to the industry distribution chart, Asian Phytoceuticals PCL ranks #35 out of 1159 companies in the Consumer Packaged Goods industry, placing it in the top 3%.
Is Asian Phytoceuticals PCL's Capex-to-Operating-Income too high?
Asian Phytoceuticals PCL's current Capex-to-Operating-Income of 0.07 is 250% above median its 10-year median of 0.02. The Consumer Packaged Goods industry median Capex-to-Operating-Income is 0.47. Asian Phytoceuticals PCL's value of 0.07 is 85.1% below this industry median. Based on the distribution chart, Asian Phytoceuticals PCL ranks #35 out of 1159 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Asian Phytoceuticals PCL has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Asian Phytoceuticals PCL's Capex-to-Operating-Income compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Asian Phytoceuticals PCL ranks #35 out of 1159 companies for Capex-to-Operating-Income. This places Asian Phytoceuticals PCL in the top 3% of its industry — outperforming the majority of peers. The industry median Capex-to-Operating-Income is 0.47. Asian Phytoceuticals PCL's value of 0.07 is 85.1% below this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 0.47, Asian Phytoceuticals PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Income for a Consumer Packaged Goods company?
The median Capex-to-Operating-Income among Consumer Packaged Goods companies is 0.47, based on 1,159 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Income significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asian Phytoceuticals PCL's current Capex-to-Operating-Income of 0.07 is 85.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Income mean?
A high Capex-to-Operating-Income can signal that a stock is expensive relative to its fundamentals. Capex to Operating Income ratio measures a company's investments in physical assets to its operating income. View historical data on Asian Phytoceuticals PCL and its competitors. For the Consumer Packaged Goods industry, the median Capex-to-Operating-Income is 0.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asian Phytoceuticals PCL's current Capex-to-Operating-Income is 0.07, which is 250% above median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asian Phytoceuticals PCL stock overvalued right now?
Asian Phytoceuticals PCL (BKK:APCO-R) has a current Capex-to-Operating-Income of 0.07. The stock's GF Value™ is ฿7.87, compared to a current price of ฿6.27 — trading 20.3% below its estimated fair value. The current Capex-to-Operating-Income is 0.07, which is 250% above median its 10-year median of 0.02 and 85.1% below the Consumer Packaged Goods industry median of 0.47. Asian Phytoceuticals PCL's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Income calculated?
Capex-to-Operating-Income is calculated from a company's financial statements. For Asian Phytoceuticals PCL (BKK:APCO-R), the current Capex-to-Operating-Income is 0.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Asian Phytoceuticals PCL (BKK:APCO-R) Overvalued in 2026?
Based on GuruFocus' analysis, Asian Phytoceuticals PCL stock appears to be undervalued.
The current stock price of ฿6.27 is trading 20.3% below its estimated GF Value™ of ฿7.87.
Key valuation signals for BKK:APCO-R:
Capex-to-Operating-Income: 0.07 (250% above median its 10-year median of 0.02)
GF Value™: ฿7.87 vs. price of ฿6.27 (20.3% below fair value)
Industry Position: 85.1% below the Consumer Packaged Goods median (#35 of 1159)
No single metric tells the full story. See the BKK:APCO-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Asian Phytoceuticals PCL engages in the manufacturing and marketing of herbal healthcare products. The company engages in the production and distribution of dietary supplements, cosmetics, and personal care products made from natural herbs. Its beauty products include skin nourishing and skin care products, hair loss treatment and hair growth products, slimming products, dietary supplements, and other nutritional products. Geographically, the company offers its services only in Thailand.
62GF Score
Get the complete analysis for BKK:APCO-R
Capex-to-Operating-Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:APCO-R has been successfully added to your 
